Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      General Practitioners, Nurses Must Stay Up-to-Date With Cancer Trends

      July 3, 2019
      By Brielle Benyon
      Article

      As the number of cancer diagnoses continues to increase across the United States it is crucial that primary care providers know when to refer patients to oncology teams.

      As the number of cancer diagnoses continues to increase across the United States — due to both improved detection methods and an aging population – it is crucial that primary care providers work with oncology teams, and know when to refer patients there, explained Nabil F. Saba, MD, FACP.

      “The role of primary care physicians and general practitioners is really key,” Saba, director of head and neck oncology at the Winship Cancer Institute, said in a recent interview with Oncology Nursing News. “Educating the general practitioners on the signs of symptoms of cancer is also going to be key in allowing the increased detection of cancer by these providers.”

      For example, Saba explained, patients who have a sore throat that does not resolve, even after a course of antibiotics, should be referred to a head and neck expert or an otolaryngologist. While this symptom might be obvious to an oncologist or oncology nurse, the patient might not be seen by one unless they are referred by their primary care provider.

      “As far as other cancers, go, it’s important for the primary care physician to keep an eye on patients who have symptoms that don’t resolve, specifically patients with a history of smoking or who are current smokers,” Saba said, explaining that they are at a higher risk for developing cancer.

      Additionally, all providers — both in the oncology unit and not – should be aware of certain health-related trends that are occurring across the nation. Saba mentioned that the incidence of oropharynx cancer, which is related to human papillomavirus, is on the rise, and has surpassed the incidence of cervical cancer as the leading HPV-related cancer in the United States.

      According to Saba, the number of oropharynx cancers will continue to increase, particularly in men over the age of 65.

      “Even though we’ve learned over the years that HPV-related cancers tend to involve a younger and healthier segment of the population — which is still true to a certain extent – the projection is that over the next couple of decades, this may not be true,” Saba said. “We need to really be on the lookout and expect this disease to increase in an older segment of the population.”

      When it comes to younger populations, particularly women between the age of 18 and 39, the HPV vaccine is decreasing the number of HPV-related cancers, such as cervical precancers, diagnosed across America.

      However, providers must still be vigilant.

      “I wish I could limit this to one set of symptoms, but I think the take home message from this is that since the population is aging, and cancer is expected to remain with high incidence in this country, primary care physicians will play a major role in trying to detect these cancers as early as possible,” Saba said.

      “Early detection of cancer is paramount to improvement in outcomes. This really applies to the majority of cancers. The earlier you detect the cancer, the earlier you can intervene, and the higher chance of curing the patient.”

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man with a beard in front of a blue background
      4 experts in this video
      4 experts in this video
      4 experts in this video
      4 experts in this video
      Image of a woman with light brown hair wearing glasses with a blue background
      Image of a woman wearing glasses in front of a blue background
      Image of a woman with glasses in front of a blue background
      Related Content

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      July 2nd 2025
      Article

      Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a laptop with the words "FDA Food and Drug Adminstration" visible

      Oncology Drugs Approved by the FDA in June

      Bridget Hoyt
      July 2nd 2025
      Article

      Oncologic therapies approved in June included indications in genitourinary, lung, and hematologic, and head and neck cancers.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a pair of lungs with tumors

      ICI Rechallenge With Anlotinib May Benefit Pretreated ES-SCLC

      Roman Fabbricatore
      July 1st 2025
      Article

      Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.


      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

      Related Content

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      July 2nd 2025
      Article

      Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a laptop with the words "FDA Food and Drug Adminstration" visible

      Oncology Drugs Approved by the FDA in June

      Bridget Hoyt
      July 2nd 2025
      Article

      Oncologic therapies approved in June included indications in genitourinary, lung, and hematologic, and head and neck cancers.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a pair of lungs with tumors

      ICI Rechallenge With Anlotinib May Benefit Pretreated ES-SCLC

      Roman Fabbricatore
      July 1st 2025
      Article

      Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.


      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.